Stock Price Forecast

Dec. 12, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Seagen Inc chart...

About the Company

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys

Exchange

NASDAQ

Website

seattlegenetics.com

$140M

Total Revenue

4K

Employees

$43B

Market Capitalization

-57.32

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SGEN News

Pfizer-Acquired Seagen's Adcetris Combo Therapy Extends Overall Survival Versus Placebo In Patients With Most Common Type Of Lymphoma

on MSN ago, source:

Pfizer Inc (NYSE:PFE) announced that a Phase 3 study of the antibody-drug conjugate Adcetris (brentuximab vedotin) combined ...

Pfizer shutting down Seagen's $350M construction project in Everett

26d ago, source: The Business Journals

The site, located at 215 Shuksan Way, was part of the $43 billion acquisition of Bothell-based Seagen Inc. (Nasdaq: SGEN), which was completed in December. About 120 employees will be laid off as ...

Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come

on MSN ago, source:

A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca ...

Seagen files patent for multi-drug antibody drug conjugates with site-specific construction

5d ago, source: Pharmaceutical Technology

Discover Seagen Inc.'s groundbreaking patent for multi-drug Antibody Drug Conjugates and Linking Assembly Units, revolutionizing targeted drug delivery in cancer treatment. Explore the innovative ...

Seagen Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

21h ago, source:

As previously disclosed, the Company remains eligible to receive contingent milestone and royalty payments across its ...

Pfizer’s Seagen takeover faces EU investigation

13d ago, source: The Star

NEW YORK: Pfizer Inc’s proposed US$43bil (RM195bil) takeover of Seagen Inc will face an investigation from the European Union’s (EU) merger enforcer, as the bloc continues to scrutinise large ...

Pfizer Is Too Cheap To Ignore

6d ago, source:

Pfizer enjoyed a cash windfall with the success of its Covid vaccine, and the company has been aggressively investing this ...

Seagen Inc. (SGEN.MX)

19d ago, source: Yahoo Finance

The top three U.S. M&A deals of 2023 by deal value include, Exxon (XOM) acquiring Pioneer (PXD), Chevron's (CVX) acquisition of Hess (HES), and Pfizer (PFE) acquiring Seagen (SGEN), according to ...

Pfizer-Acquired Seagen's Adcetris Combo Therapy Extends Overall Survival Versus Placebo In Patients With Most Common Type Of Lymphoma

15d ago, source: Benzinga.com

Positive outcomes were also observed in key secondary endpoints, including progression-free survival and overall response rate. Diffuse large B-cell lymphoma is the most common type of lymphoma ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...